Trial Profile
Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Expanded access; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 31 Oct 2018 Status changed from recruiting to completed.
- 14 Sep 2017 New trial record